NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 305 filers reported holding NOVOCURE LTD in Q3 2022. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $744 | -60.9% | 46,084 | +0.5% | 0.00% | -60.0% |
| Q2 2023 | $1,903 | -29.9% | 45,854 | +1.5% | 0.01% | -33.3% |
| Q1 2023 | $2,716 | -17.4% | 45,164 | +0.7% | 0.02% | -25.0% |
| Q4 2022 | $3,289 | -99.9% | 44,844 | +1.3% | 0.02% | -9.1% |
| Q3 2022 | $3,364,000 | +10.8% | 44,274 | +1.3% | 0.02% | +15.8% |
| Q2 2022 | $3,037,000 | -2.8% | 43,704 | +15.9% | 0.02% | +11.8% |
| Q1 2022 | $3,124,000 | -31.9% | 37,709 | -38.3% | 0.02% | -29.2% |
| Q4 2021 | $4,586,000 | -21.7% | 61,081 | +21.2% | 0.02% | -29.4% |
| Q3 2021 | $5,854,000 | -39.2% | 50,389 | +16.1% | 0.03% | -39.3% |
| Q2 2021 | $9,629,000 | +90.3% | 43,410 | +13.4% | 0.06% | +75.0% |
| Q1 2021 | $5,061,000 | -23.8% | 38,290 | -0.2% | 0.03% | -27.3% |
| Q4 2020 | $6,638,000 | +58.0% | 38,360 | +1.6% | 0.04% | +37.5% |
| Q3 2020 | $4,201,000 | +84.1% | 37,740 | -1.9% | 0.03% | +68.4% |
| Q2 2020 | $2,282,000 | – | 38,490 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $77,833,000 | 15.51% |
| HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
| Darsana Capital Partners LP | 700,000 | $155,274,000 | 4.42% |
| MORGAN JESS S & CO INC | 23,775 | $5,274,000 | 3.47% |
| Soleus Capital Management, L.P. | 98,975 | $21,955,000 | 3.38% |
| Montanaro Asset Management Ltd | 116,650 | $25,875,000 | 3.26% |
| Taylor Frigon Capital Management LLC | 31,035 | $6,884,000 | 2.15% |
| Rhenman & Partners Asset Management AB | 120,000 | $26,618,000 | 1.81% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $2,218,000 | 1.33% |
| Derbend Asset Management | 5,789 | $1,284,000 | 1.20% |